288 related articles for article (PubMed ID: 30195018)
1. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
[TBL] [Abstract][Full Text] [Related]
2. Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway.
Xu X; Rajamanicham V; Xu S; Liu Z; Yan T; Liang G; Guo G; Zhou H; Wang Y
Biomed Pharmacother; 2019 Jul; 115():108922. PubMed ID: 31048190
[TBL] [Abstract][Full Text] [Related]
3. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
4. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
5. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
6. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
[TBL] [Abstract][Full Text] [Related]
7. Schisandrin B displays a protective role against primary pulmonary hypertension by targeting transforming growth factor β1.
Wu J; Jia J; Liu L; Yang F; Fan Y; Zhang S; Yan D; Bu R; Li G; Gao Y; Chen Y
J Am Soc Hypertens; 2017 Mar; 11(3):148-157.e1. PubMed ID: 28117274
[TBL] [Abstract][Full Text] [Related]
8. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
9. Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.
Yang X; Wang S; Mu Y; Zheng Y
Oncol Rep; 2016 Oct; 36(4):1799-806. PubMed ID: 27499090
[TBL] [Abstract][Full Text] [Related]
10. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.
Liu Z; Zhang B; Liu K; Ding Z; Hu X
PLoS One; 2012; 7(7):e40480. PubMed ID: 22848381
[TBL] [Abstract][Full Text] [Related]
11. Schisandrin B inhibits TGF-β1-induced epithelial-mesenchymal transition in human A549 cells through epigenetic silencing of ZEB1.
Zhuang W; Li Z; Dong X; Zhao N; Liu Y; Wang C; Chen J
Exp Lung Res; 2019; 45(5-6):157-166. PubMed ID: 31268360
[No Abstract] [Full Text] [Related]
12. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of schisandrin B against cyclosporine A-induced nephrotoxicity in vitro and in vivo.
Zhu S; Wang Y; Chen M; Jin J; Qiu Y; Huang M; Huang Z
Am J Chin Med; 2012; 40(3):551-66. PubMed ID: 22745070
[TBL] [Abstract][Full Text] [Related]
14. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
[TBL] [Abstract][Full Text] [Related]
15. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
17. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
Chun J; Li RJ; Cheng MS; Kim YS
Cancer Lett; 2015 Feb; 357(1):393-403. PubMed ID: 25434800
[TBL] [Abstract][Full Text] [Related]
18. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
[TBL] [Abstract][Full Text] [Related]
19. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
20. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
